NCT03723499

Brief Summary

Carcinoid tumors of the lung are considered to be a low-grade malignancy. Surgical resection is considered the standard approach. Recent data has shown that a complete endoscopic treatment could be considered. An endoscopic treatment is can be a alternative to invasive surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 1995

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 1995

Completed
22.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

October 26, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 29, 2018

Completed
Last Updated

October 29, 2018

Status Verified

October 1, 2018

Enrollment Period

22.1 years

First QC Date

October 26, 2018

Last Update Submit

October 26, 2018

Conditions

Carcinoid Tumor

Keywords

Carcinoid tumorsEndoscopic treatmentRecurrence

Outcome Measures

Primary Outcomes (1)

  • Complete endoscopic treatment

    patients who have a complete endoscopic treatment

    Month 1

Secondary Outcomes (3)

  • Type of endoscopic method used

    Month 1

  • Tumor localization

    Month 1

  • Deadline before recurrence

    10 years

Study Arms (1)

endoscopic treatment

Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.

Other: Medical data collection

Interventions

Medical data collectionOTHER

Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes

endoscopic treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients treated by endoscopic approach for a carcinoid tumor will be included.

You may qualify if:

  • Patients treated by endoscopic approach for a carcinoid tumor at the University Hospital Centre of Saint-Etienne between November 1995 to December 2017.

You may not qualify if:

  • Patients treated for a recurrence of carcinoid tumor.
  • Patients with metastatic disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Saint-Etienne

Saint-Etienne, 42055, France

Location

MeSH Terms

Conditions

Carcinoid TumorRecurrence

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jean-Michel VERGNON, PhD

    CHU SAINT-ETIENNE

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 26, 2018

First Posted

October 29, 2018

Study Start

November 1, 1995

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

October 29, 2018

Record last verified: 2018-10

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)